TEAM LEADER
Immunotherapy and anti-angiogenic therapy in oncology
Mail : eric.tartour@inserm.fr
PHONE :+33 156093942
After an MD, PhD course, he was first trained at the Institut Curie for 10 years on cancer immunotherapy. Eric Tartour is currently head of the immunology department at the Hôpital Européen Georges Pompidou and the Hôpital Necker. He is a professor of immunology at the Université Paris Cité and director of an INSERM team at PARCC (INSERM U970). He is working on the identification of predictive biomarkers for cancer immunotherapy combined or not with anti-angiogenic treatment and the development of mucosal vaccine. Its main contributions concern the interest of targeting dendritic cells to promote vaccine responses, the ambivalent role of Il-17 in cancer, the identification of resident memory T cells as a new vaccine target, The soluble sCD27 as a novel predictive biomarker, the role of VEGF as an immunosuppressive molecule.
2020-to present day : Deputy Director (Research and training) DMU Biophygen GH Paris Centre.
2017-to the present day : Professor in immunology (Exceptional class) : Medical School of the University Paris Descartes.
2011-to the present day : Head Lab of immunology (responsible vaccine immunomonitoring platform). Hopital Européen Georges Pompidou (HEGP). Paris. France.
1992-2000 : Physician Specialized in Immuno-Oncology : Institut Curie.
2022-to the present day : Head Department of Immunology. Hopital Européen Georges Pompidou and Hopital Necker.
My 2 main research areas are i) the optimisation of mucosal vaccines against cancer or infections. We aim to understand the priming mechanism after nasal immunisation by evaluating the role of resident memory T cells and by using different vaccine tools: Shiga toxin B subunit targeting dendritic cells, mucosal adjuvants and mRNA (Nat Commun 2013, Sci Transl Med 2017, JITC 2021, Toxins 2022) ii) Improving clinical response to immunotherapy by identifying biomarkers of the tumour microenvironment using multiplexed in situ techniques or in relation to blood biomarkers (Cancer Res 2017, Cells 2021, Clin Cancer Res 2022). We are also trying to combine these immunomodulatory treatments with anti-angiogenic molecules or by modulating a pro-atherogenic diet for which the laboratory has shown the immunosuppressive role (Nat Commun 2022, Oncoimmunol 2022, Cancers 2021).
